Home
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
About
- Overview
- Organization
News
Investors
Contact

Oblique Therapeutics > News > 2019 > March

Home
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
About
- Overview
- Organization
News
Investors
Contact

News

Archive

June 2020
November 2019
October 2019
July 2019
March 2019
January 2019
November 2018
October 2018
September 2018
April 2018
February 2018
December 2017

Categories

Company updates
News

28 Mar 2019

We welcome our new owners

07 Mar 2019

New collaboration with Pharma

Copyright © 2020 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu

Home
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
About
- Overview
- Organization
News
Investors
Contact

About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises three in-house programs – two antibody candidates: aKRAS in advanced cancer, aTRPA1 in pain; and the small molecule OT-1096 in triple-negative breast cancer. In addition, there are three antibodies programs in collaboration with pharma. Oblique Therapeutics makes medicines that matter to patients.

We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies

Approve